Trial
NCT02566603
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Protalex, Inc.
Collaborators
—
Condition
Immune Thrombocytopenia
Intervention
PRTX-100
Why stopped
Enough data has been collected to allow analysis of the safety profile and risk-benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-25